Subscribe To
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J. and SAN DIEGO, April 16, 2023 (GLOBE NEWSWIRE) — Merck (NYSE: MRK), known as MSD outside the United States and Canada, […] The post Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. appeared first on...
Read More
Posted: Apr 16 2023, 10:00
Author Name: forextv
Views: 103081